SCMOM 2012_NeoStem NeoStem, Inc. is an emerging technology leader in the fast-developing cell therapy market. Its business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC, with a medically important cell therapy product development program. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at its Amorcyte subsidiary, which is enrolling patients in a Phase 2 trial for preservation of heart function after a heart attack. Athelos Corporation, also a NeoStem subsidiary, is in early stage clinical exploration of a T-cell therapy for autoimmune conditions. Pre-clinical assets include our VSELTM Technology platform and our mesenchymal stem cell product candidate for regenerative medicine. http://www.neostem.com Presenter: Jonathan Sackner-Bernstein, NeoStem, Inc.From:AllianceRegenMedViews:4 1ratingsTime:14:54More inScience Technology Continued here: SCMOM 2012_NeoStem - Video … Continue reading →

SCMOM 2012_Regen BioPharma, Inc. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials). The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 18 - 24 months grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma. http://www.regenbiopharma.com Presenter: J. Christopher Mizer, President, Regen BioPharma, Inc.From:AllianceRegenMedViews:4 1ratingsTime:09:13More inScience Technology Read the original post: SCMOM 2012_Regen BioPharma, Inc. - Video … Continue reading →

PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ --RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth." Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York. The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit. The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, … Continue reading →

SCMOM 2012_AlloSource AlloSource, a non-profit organization, offers more than 200 types of precise bone, skin, soft-tissue and custom-machined allografts for use in life-saving and life-enhancing medical procedures. The world's leader in fresh cartilage tissue and skin allografts, the company developed a cleansing process for fresh tissue grafts that does not destroy live cells. Most recently, AlloSource created a technique to recover mesenchymal stem cells from cadaveric adipose tissue, which led to the development of its own stem cell product, AlloStem Stem Cell Bone Growth Substitute. AlloSource is registered with the FDA, accredited by the American Association of Tissue Banks and is compliant with all applicable state regulations and with the ISO 9001:2008 standard. http://www.allosource.org Presenter: Kevin Cmunt, Executive Vice President, AlloSourceFrom:AllianceRegenMedViews:2 1ratingsTime:14:35More inScience Technology Continued here: SCMOM 2012_AlloSource - Video … Continue reading →

Americord Registry Offers Exclusive Service Preserving Stem Cells From Cord Tissue and Placenta Tissue New York, NY (PRWEB) November 26, 2012 MSCs, which can easily be harvested from umbilical cord tissue and placenta tissue when a baby is born, are in fact currently the subject of over 200 clinical trials. While MSCs are not yet being used for medical therapies, research has indicated that they hold the promise of being able to someday treat debilitating conditions such as heart disease, type 1 diabetes, lung cancer, Parkinsons Disease, and injuries to bones and cartilage. Americord Registry offers the ability to preserve MSCs. We are committed to helping parents-to-be expand their babys options for future medical treatment, said Americord CEO Martin Smithmyer. Offering the option to preserve MSCs from umbilical cord tissue and placenta tissue is just one of the ways that we are pioneering best-in-class services in the cord blood industry. We are also working closely with scientists to develop a proprietary product that will significant increase the volume of stem cells that can be preserved when a baby is born. Americord Registry also offers the ability to preserve stem cells from umbilical cord blood. Parents-to-be can preserve stem cells from … Continue reading →

Washington, November 28 (ANI): When mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy, a study has found. The study, carried out by researchers at Oslo University Hospital and the Norwegian Center for Stem cell Research, Oslo University, sought to determine if MSCs from different organs would result in different functional outcomes. "Despite advances in revascularization and medical therapy, acute myocardial infarction (AMI) and heart failure are still important causes of morbidity and mortality in industrialized countries," said study co-author Dr. Jan E. Brinchmann of the Norwegian center for Stem Cell Research at Oslo University Hospital, Oslo. "AMI leads to a permanent loss of contractile elements in the heart and the formation of fibrous scarring. Regeneration of contractile myocardium has been a target of cell therapy for more than a decade," he added. According to Dr. Brinchmann, MSCs tolerate hypoxia, secrete angiogenic factors and have been shown to improve vascularization; thus, they have properties suggesting that they may beneficially impact AMI, chronic … Continue reading →

Public release date: 27-Nov-2012 [ | E-mail | Share ] Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair Putnam Valley, NY. (Nov. 27, 2012) A study published in the current issue of Cell Transplantation (21:8), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, has found that when mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy. The study, carried out by researchers at Oslo University Hospital and the Norwegian Center for Stem cell Research, Oslo University, sought to determine if MSCs from different organs would result in different functional outcomes. "Despite advances in revascularization and medical therapy, acute myocardial infarction (AMI) and heart failure are still important causes of morbidity and mortality in industrialized countries," said study co-author Dr. Jan E. Brinchmann of the Norwegian center for Stem Cell Research at Oslo University Hospital, Oslo. "AMI leads to a permanent loss of contractile elements in the heart and the formation of fibrous scarring. Regeneration of contractile myocardium has … Continue reading →